secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034907
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway
---------------------------------------------------------------------------

- Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.
- Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.
- Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.
- DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/0001437749-24-034907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924034907/acrx20241112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer